Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
BeOne Medicines
BeOne Medicines
Lyell Immunopharma, Inc.
Aurigene Discovery Technologies Limited
AstraZeneca
Thammasat University
Pfizer
Novartis
AVM Biotechnology Inc
New York Medical College
BeOne Medicines
Columbia University
Nurix Therapeutics, Inc.
Verismo Therapeutics
Germans Trias i Pujol Hospital
Janssen Research & Development, LLC
Regeneron Pharmaceuticals
Genmab
Copenhagen University Hospital, Hvidovre
Elixiron Immunotherapeutics (Hong Kong) Ltd.
National Institutes of Health Clinical Center (CC)
The University of Hong Kong
Debiopharm International SA
Vironexis Biotherapeutics Inc.
Health Institutes of Turkey
AstraZeneca
University of Cincinnati
University of Miami
Nurix Therapeutics, Inc.
Korea University
AstraZeneca
BeOne Medicines
Massachusetts General Hospital
University of Washington
Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Regeneron Pharmaceuticals
Sichuan Huiyu Pharmaceutical Co., Ltd
Nuvation Bio Inc.
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Cho Pharma Inc.
Tempus AI
ModeX Therapeutics, An OPKO Health Company
Indiana University
Ipsen
Neonc Technologies, Inc.
Fred Hutchinson Cancer Center
AstraZeneca
Karolinska Institutet